OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into an exclusive license agreement whereby OBI grants rights of OBI-999, a novel antibody-drug conjugate, and OBI-833, a […]